Magazine article from our research archive:

Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules

Antibody drug conjugates offer a niche opportunity in drug development and contract manufacturing.

Targeted therapies such as monocolonal antibodies are an important part of anticancer drug development. Humanized antibodies may be used either alone in unlabeled or naked form or conjugated with radioactive isotopes, chemotherapeutics, or toxins to create highly targeted agents. Antibody drug conjugates (ADCs), or monoclonal antibodies linked to a cytotoxic small molecule, provide a niche opportunity for biopharmaceutical companies and contract manufacturers.

Monclonal antibodies target cancer

Six engineered monoclonal antibodies ["Rituxan" (rituximab), "Herceptin" (trastuzumab), "Campath" ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!